Patent · US Active

Control of gene expression

US8168774B2 · kind B2 · utility

16Cited by
94References
76Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 2, 2005
Grant dateMay 1, 2012
Priority date
Expiry dateNov 11, 2026

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2840/20
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates generally to a method of modifying gene expression and to synthetic genes for modifying endo gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the invention utilizes recombinant DNA technology to post-transcriptionally modify or modulate the expression of a target gene in tissue, organ or whole organism, thereby producing novel phenotypes. Novel synthetic genes and genetic constructs which are cap repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.